Last reviewed · How we verify

Xilytol tablet to limit dental biofilm

Universidade Federal do Rio de Janeiro · Phase 2 active Small molecule

Xilytol tablet to limit dental biofilm is a Small molecule drug developed by Universidade Federal do Rio de Janeiro. It is currently in Phase 2 development. Also known as: Xylitol tablet.

At a glance

Generic nameXilytol tablet to limit dental biofilm
Also known asXylitol tablet
SponsorUniversidade Federal do Rio de Janeiro
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Xilytol tablet to limit dental biofilm

What is Xilytol tablet to limit dental biofilm?

Xilytol tablet to limit dental biofilm is a Small molecule drug developed by Universidade Federal do Rio de Janeiro.

Who makes Xilytol tablet to limit dental biofilm?

Xilytol tablet to limit dental biofilm is developed by Universidade Federal do Rio de Janeiro (see full Universidade Federal do Rio de Janeiro pipeline at /company/universidade-federal-do-rio-de-janeiro).

Is Xilytol tablet to limit dental biofilm also known as anything else?

Xilytol tablet to limit dental biofilm is also known as Xylitol tablet.

What development phase is Xilytol tablet to limit dental biofilm in?

Xilytol tablet to limit dental biofilm is in Phase 2.

Related